Below you'll find a list of all posts that have been tagged as “life sciences”
A U.S.-based biopharmaceutical company faced competitive pressure from upcoming cardiovascular product launches and looming generic entry. Sedulo Group delivered targeted intelligence on competitor strategies, generic threats, and market vulnerabilities through a customized monitoring program. Armed with these insights, the client implemented counter-launch tactics, adjusted pricing and distribution, and protected its market position
In unpredictable markets, resilience isn’t optional, it’s essential. This piece explores how economic and regulatory shocks test corporate strategies and why embedding agility and cross-functional coordination into CI frameworks empowers companies to weather turbulence and stay nimble.
At the Pharma CI Conference (Sept 25–26, 2024), leaders discussed how shifts like the IRA’s impact on drug pricing, AI in R&D, and shifting regulatory regimes are reshaping life sciences CI. Read this summary to grasp the conference’s breakout trends and strategic implications.
Combine secondary data (clinical registries, financial filings) with primary intelligence (expert interviews) to build a 360° view of your competitive environment. These integrated methods enable triangulated, validated insights into competitor strategies, commercial infrastructure, and trial dynamics
Through analysis of IO clinical trials (2018–2022), we reveal how top‑20 pharma concentrate on mAb trials globally, while smaller firms explore innovative modalities like BsAb and CAR‑T, and how China is emerging as an IO hub. These patterns offer strategic cues for reshaping your trial portfolio and R&D focus.
This first article, part of a three-post series, focusses on need for such a meeting and underlines the impact of accelerated approvals in the field of Oncology.
The COVID-19 pandemic has had a very strong impact on all global economies across multiple sectors. Its impact on the US Pharma industry was significant in the first quarter, causing most companies to adjust and realign their businesses in response to the outbreak. The pandemic not only had a direct impact on Q1 revenues, but also affected overall drug development …
Before COVID-19 transpired executives were concerned with their strategic assumptions and the results of getting them wrong. A February 2020 Gartner study cited lack of confidence in strategic assumptions as the leading corporate risk among senior executives across a diverse set of industries and global geographies in Q4 2019. A strategic assumption can be defined as the unstated belief that something is likely to occur to enable an achievable strategic goal. Depending on the …
The COVID-19 outbreak generated widespread concern over how pharmaceutical, biotechnology, and medtech companies would cope with stringent national and regional lockdowns. Financial results from Q1 provide the first indicator of how this public health crisis will impact this industry and what the future may hold. By early May, earnings for most of the significant players in the pharma industry had been announced, …
Over the last several years there have been a number of interesting articles written about breaking down information silos, in fact, I have even used that term myself in the past. However, the more I work with clients attempting to overcome the information silo dilemma, I am convinced the emphasis should instead be on connecting information silos. Let’s face it, …
